Pacific Biosciences, formerly known as Nanofluidics, a Menlo Park, Calif. company focused on medications resulting from DNA gene sequencing, has raised around $50 million in a forth round of funding.
Investors include Maverick Capital, and return backers Alloy Ventures, Kleiner Perkins Caufield & Byers and Mohr, Davidow Ventures, according to PE Week, which first reported the funding today. Pacific Biosciences previously has raised more than $15M.
Here is an article about its technology (free after registration).
(This story first posted 1/12)
Tags: co:Pacific-Biosciences, Davidow-Ventures, deal, inv:Alloy-Ventures, inv:Kleiner-Perkins-Caufield-&-Byes, iv:MohrOne Comment
-
Mark Wendman said:
See the website link to the short article on Pacific Biosciences I did back in May 2006, with a quick overview of some key Cornell patents likely used by PacBio. There are links to patents and excerpted drawings from some ….
The firm has an interesting application of near field optical methods, derived from recent use of tapered optical fiber NSOM probes, but in a fixed optical configuration of an array of sub optical light apertures, imaged by a staring camera.
Given the renewed funding, hopefully their apparent prior challenges of signal to noise (alluded to in career postings) have been solved, before this larger round.
One Trackback
10:04 am
VentureBeat » Pacific Bio lifts the veil on its high-speed genome-sequencing effort said:
[...] Ventures. (Our earlier coverage of the company’s $50 million financing last year is here.) A research team including scientists from PacBio — then known as NanoFluidics — and [...]